Particle Therapy 2017

Protons in pediatrics Clinical experience

AUTHOR [Ref] (Year)

# Pts (F-UP)

TOTAL DOSE, (CGE)

SITE/ TUMOUR TYPE

RESULTS

Mc Allister, B [ 33] (1997)

HN+brain

28 (m:25)

m: 54 (41-70) mix P/X+P

CL:24/28, 2 épilepsies, 1 hormon failure, 1 cataract

Hug, EB [34] (2002)

Astrocytomas Low grade

27 (M:39)

M:55 (50-63) X/X+P

OS: 85%, LC: 78%, Complic : 4/27 pituitary failures, 1 radiological radionecrosis

Hug, EB [35] (2002)

Skull base sarcomas

29

50-78

CL/SG 5A: 72%-56%; complic:2 sensori-motor deficits

Noel, G [36] (2003)

CNS

17 (M:27)

m:60 (50-69) X+P

LC + OS 3Y:92%+93%; Complic : 1 cerebellar, 1 pituitary failure, 1 memory loss

Yock, T [32] (2005)

RMS orbit

7 (m:75)

m: 46 (40-55) P

LC: 6/7; no late toxicity

Luu, QT [37] (2006)

Craniopharyngioma

16 (M:60)

? (50-59) P

CL: 14/15; SG:12/15; complic: pituitary failure, 1 vascular, 1 meningioma,

Timmermann, B [38] (2007)

Trunk+HN sarcomas

16 (m:18)

m:50 (46-61) P

LC:12/16

Habrand, JL [39] (2008)

Skull base sarcomas

30 (M:26)

M: 68, P/X+P

OS/DFS 5A: Chordomas: 81%/77%; chondrosarcomas: 100%/100%; pituitary failures: half, 1 visual loss